布地奈德联合特布他林治疗小儿支气管哮喘的疗效及安全性

摘要

目的:探讨布地奈德联合特布他林治疗小儿支气管哮喘的疗效及安全性.方法:选取2016年2月至2018年2月湖北省谷城县人民医院收治的小儿支气管哮喘患者84例, 随机分为观察组和对照组, 每组42例.观察组患儿给予吸入用布地奈德混悬液联合硫酸特布他林雾化液治疗, 对照组患儿仅给予吸入用布地奈德混悬液治疗.比较两组患儿的临床疗效、临床症状缓解时间、不良反应发生情况及复发情况的差异.结果:观察组患儿的总有效率为92.86％ (39/42), 明显高于对照组的80.95％ (34/42), 差异有统计学意义 (P＜0.05);观察组患儿喘息、咳嗽及胸闷缓解时间明显短于对照组, 差异均有统计学意义 (P＜0.05);观察组患儿的不良反应发生率、复发率分别为7.14％ (3/42) 、4.76％ (2/42), 明显低于对照组的21.43％ (9/42) 、16.67％ (7/42), 差异均有统计学意义 (P＜0.05).结论:布地奈德联合特布他林治疗小儿支气管哮喘的疗效显著, 可有效缓解症状, 降低不良反应发生率和复发率, 改善预后.%OBJECTIVE: To probe into the efficacy and safety of budesonide combined with terbutaline in treatment of children with bronchial asthma. METHODS: 84 children with bronchial asthma admitted into Hubei Gucheng County People's Hospital from Feb. 2016 to Feb. 2018 were extracted to be randomly divided into observation group and control group, with 42 cases in each. The observation group was treated with inhalation budesonide suspension combined with terbutaline sulfate nebulized solution, and the control group only received budesonide suspension for inhalation. The clinical efficacy, relief time of clinical symptoms, incidence of adverse drug reactions and recurrence of two groups were compared. RESULTS: The total effective rate of the observation group was 92.86％ (39/42), significantly higher than that of the control group (80.95％, 34/42), the difference was statistically significant (P＜0.05). The relief time of wheezing, coughing and chest distress in the observation group was significantly shorter than that in the control group, with statistically significant differences (P＜0.05). The incidence of adverse drug reactions and recurrence in the observation group were 7.14％ (3/42) and 4.76％ (2/42), significantly lower than those in the control group [21.43％ (9/42) and 16.67％ (7/42) ], the difference was statistically significant (P＜0.05). CONCLUSIONS: The efficacy of budesonide combined with terbutaline in treatment of children with bronchial asthma is significant, which can effectively alleviate the clinical symptoms, reduce the incidence of adverse drug reactions and recurrence, and improve the prognosis.